Mubadala Investment Company, in collaboration with CBC Group, has obtained full ownership of UCB Pharma’s mature business in China.
UCB Pharma, headquartered in Belgium, is a global biopharmaceutical leader in the growing immunology, neurology, and rare disease sectors in China.
The acquisition includes UCB’s neurology and allergy portfolios in Mainland China, along with the Zhuhai manufacturing site. In 2023, these medicines generated combined net sales of 131 million euros in China. The completion of the transaction is expected in Q4 2024, subject to regulatory approvals and customary conditions.
This acquisition is part of Mubadala’s strategy to expand in Asia through strategic investments in high-growth sectors.
Mohamed Albadr, Head of China at Mubadala, said, “We are thrilled to partner with CBC Group to support the next phase of UCB’s platform as it scales to a leading entity in China and delivers transformative medicines to the markets. The company’s dedication to clinical excellence and innovation aligns with our commitment to enhancing access to care and growth in the healthcare system.”
Mina Hamoodi, Head of Healthcare at Mubadala, said, “CNS is a large and growing therapeutic area in China that has an urgent clinical need. We look forward to building out a broader CNS-focused platform to benefit the China market.”
Jean-Christophe Tellier, CEO at UCB, commented, “We are convinced that Mubadala and CBC Group are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China.”
